Top Markets
#1 Black Phoenix Black Phoenix +824.20%
#2 Not in Employment, Education, or Training Not in Employment, Education, or Training +25.37%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.97%
#4 Prom Prom +20.14%
#5 Magma Finance Magma Finance +19.82%
#6 SAFEcoin SAFEcoin +19.77%
#7 Beam Beam +18.79%
#8 pipedog pipedog +17.11%
#9 Bless Bless +17.08%
#10 YFSX YFSX +15.57%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
CymaBay Therapeutics, Inc. CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc.

CBAY
Classifica tra le azioni #6078
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Prezzo delle azioni
$32.48
Ultima sincronizzazione: 2024-03-25
Capitalizzazione di mercato
$2.24B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia CymaBay Therapeutics, Inc. (CBAY)

Categoria

Healthcare
Storico del prezzo dell'azione per CymaBay Therapeutics, Inc. (CBAY)
Prezzo di chiusura più alto: $32.39 il 2024-03-01

Prezzo di chiusura più basso: $9.00 il 2014-02-01
Storico del prezzo dell'azione di CymaBay Therapeutics, Inc. dal 2014 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2024 47.52%
2023 374.76%
2022 35.77%
2021 -49.78%
2020 272.39%
2019 -77.25%
2018 -6.63%
2017 374.80%
2016 15.85%
2015 -81.43%
2014 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $547.65 40.75%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.06K 49.04%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.63 -12.65%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $143.63 472.23%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $765.25 7.19%
CH